Oncology

Latest News

The new report suggests the C5a-C5aRq axis might be a useful target in combination with existing therapies for cutaneous squamous cell carcinoma. | Image credit: vladimircaribb - stock.adobe.com

C5aR1 Flagged as Biomarker in Cutaneous Squamous Cell Carcinoma

By Jared Kaltwasser

June 7th 2025

The findings are notable in part because therapies have already been approved to target C5aR1 in other diseases.

The study identified several molecular markers related to SCLC prognosis by integrating somatic mutation profiles, mRNA transcriptome data, and clinical information. | Image credit: vitstudio - stock.adobe.com

Novel Biomarkers May Inform Prognosis in SCLC

By AJMC Contributor

June 6th 2025

Structured exercise programs should be a part of the standard of care for colon cancer following adjuvant chemotherapy, authors of the COMMANDS study recommended. | Image credit: Drazen - stock.adobe.com

Structured Exercise Program Improves Outcomes, Quality of Life in Colon Cancer

By Rose McNulty

June 6th 2025

young adult cancer | Image credit: Roswell Park Cancer Center

ASCO Sessions Explore Data and Dynamics of Early-Onset Cancer

By Mary Caffrey

June 6th 2025

FDA headquarters | Image Credit: - Tada Images- stock.adobe.com

5 Key FDA Approval Dates Mark a Milestone-Filled May

By Brooke McCormick

June 6th 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Watch Now

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

October 18th 2019

This Week in Managed Care: October 18, 2019

This week, the top managed care news included a new guide that balances curbs on opioid abuse with the needs of patients with chronic pain; HHS proposed reforming antikickback rules to help boost value-based care; a report found flaws with Medicaid work requirements.

October 17th 2019

ASTRO Calls for Voluntary Start, Scaling Back Excessive Cuts in CMS' Proposed Radiation Oncology Model

Paul Harari, MD, FASTRO

In a commentary adapted from the organization's official response to CMS' proposal, the author highlights potential challenges that proposed alternative payment model presents for members of the American Society for Radiation Oncology (ASTRO).

October 17th 2019

Real-World Evidence: Research Reveals a Lack of Racial Diversity in Clinical Trials for Cancer Drugs

Matthew Gavidia

October 17th 2019

Screening and Prevention: More Data Reveal Shift to Obesity-Related Cancers in Younger Patients

Mary Caffrey

Although results of other recent studies have noted the rise in the rate of obesity-related cancers among younger adults, this is the first study to also find a concurrent decrease in the rate of new cancer cases among patients 65 years and older.

October 17th 2019

Bradley Prechtl Highlights the Importance of Offering Clinical Trials

Offering clinical trials is paramount, explained Bradley Prechtl, MBA, chief executive officer of Florida Cancer Specialists and the American Oncology Network.

October 17th 2019

How Obesity Affects Cancer Treatment, and How to Talk With Patients About Prevention

An Interview With Debra Patt, MD, MPH, MBA, by Jaime Rosenberg

Debra Patt, MD, MPH, MBA, an oncologist who specializes in breast cancer and who serves as executive vice president at Texas Oncology, discusses the effect of obesity on cancer treatment as well as prevention strategies.

October 16th 2019

Obesity and Cancer Risk: A Public Health Crisis

Alexander J. Alvarnas Joseph C. Alvarnas, MD

Obesity is associated with a number of adverse health-related complications and carries an elevated individual all-cause mortality risk. It would be hard to overstate the increased adverse health outcomes for obese individuals. What is far less well recognized by the general public is the significant link between obesity and increased cancer risk.

October 15th 2019

Tesh Khullar: How Community Oncologists Can Get Ahead of Changes in Reimbursement for Biosimilars

Practices are going to have to decide which biosimilar manufacturers they want to be able to partner with, explained Tesh Khullar, senior vice president & advisor, Flatiron Health.

October 15th 2019

NASH and Liver Cancer: The New Cancer Headline

Donna Cryer, JD

The most common primary liver cancer, hepatocellular carcinoma, is driven by fatty liver disease and is among the most prevalent and deadly of cancers driven by obesity. Rising rates of overweight and obesity parallel increased rates of obesogenic cancers, which increased 7% between 2005 and 2014.

October 15th 2019

MBC Treatment Not Aligned With NCCN Guidelines Leads to Higher Patient Cost Responsibility

Allison Inserro

Patients on Medicare with metastatic breast cancer who receive treatment that is discordant with NCCN guidelines bear a greater burden of patient cost responsibility than patients who do receive care according to treatment guidelines.

October 14th 2019

Erich Mounce: Partnerships and Performance Data Can Initiate Sustainable Growth in Clinical Practice

Initiating sustainable growth in clinical practices can be difficult, but through economies of scale derived from partnerships and performance data collection, optimal care can be administered efficiently, said Erich Mounce, chief operating officer, OneOncology.

October 13th 2019

Dr Amila Patel: How Flatiron's Clinical Workflow Efforts Will Expand Beyond EHRs

Amila Patel, PharmD, BCOP, technical lead, Clinical Oncology, Flatiron Health, discusses how Flatiron is working to implement clinical workflow features that expand beyond the electronic health record (EHR).

October 11th 2019

Trends in Oncology Dr Michael Kolodziej Expects to See in Coming Years

Michael Kolodziej, MD, vice president and chief innovation officer at ADVI Health, Inc., outlines the trends he expects to see in the coming years that will impact oncology.

October 8th 2019

Dr James Hamrick: There's Been Progress in Patient-Centered Care, Albeit Slow

The healthcare system has gotten better at placing more of a priority on patient-centered care, but the progress has been slow, said James Hamrick, MD, senior medical director at Flatiron Health.

October 7th 2019

Nobel Prize Honors 3 Who Showed How Cells Adapt to Oxygen Levels

Mary Caffrey

The mechanism studied affects a broad range of physiological responses and is now the focus of intense study by the pharmaceutical industry.

October 6th 2019

Dr Lawrence Shulman Discusses the Role of Rising Drug Costs in Value-Based Care

Lawrence N. Shulman, MD, director of the Center for Global Cancer Medicine at the Abramson Cancer Center, and professor of Medicine at the Hospital of the University of Pennsylvania, explains how providers are reacting to more effective, more costly therapies entering the cancer landscape.

October 5th 2019

Nina Chavez on How CAR T, Other Expensive Therapies Create Reimbursement Challenges

Nina Chavez, MBA, FACMPE, chief operating officer, New Mexico Oncology Hematology Consultants, Ltd., explains how expensive therapies like chimeric antigen receptor (CAR) T-cell therapy are creating reimbursement challenges.

October 2nd 2019

Implementing Practice Transformation, Integrating Primary Care to Provide High-Quality Cancer Care

Jaime Rosenberg

As practices work to provide the best care for their patients while also containing costs, it has become clear that the old ways of doing things won’t cut it.

September 30th 2019

Nina Chavez: OCM Has Made Community Oncologists Better Business People

The Oncology Care Model (OCM) over the last couple of years has helped us to look at things that we didn’t really think of from an oncology perspective, explained Nina Chavez, MBA, FACMPE, chief operating officer, New Mexico Oncology Hematology Consultants, Ltd.

September 29th 2019

Tesh Khullar Discusses the Emerging Role of Biosimilars in Oncology

Tesh Khullar, senior vice president & advisor, Flatiron Health, discusses the first to anticancer biosimilars having recently entered the market.

September 27th 2019

Defining, Standardizing, and Acting on Patient-Reported Outcomes in Cancer Care

Jaime Rosenberg

During a panel discussion on defining, standardizing, and reporting quality in cancer care during the National Comprehensive Cancer Network Policy Summit held September 12 in Washington, DC, it became clear that stakeholders of all backgrounds have set their focus on one type of metric in particular: patient-reported outcomes.

September 27th 2019

Facilitating the Qualitative Improvement of Oncology Through Value-Based Care

Matthew Gavidia

Coverage of the first half of the Institute for Value-Based Medicine® (IVBM®) session held September 19, 2019, in Philadelphia, Pennsylvania. IVBM® is an initiative of The American Journal of Managed Care®.

September 22nd 2019

Dr Blase Polite Outlines the Decision to Move to 2-Sided Risk in the OCM

CMS is trying to make a 2-sided risk model in the Oncology Care Model enticing for practices, but there is still a lot of math practices need to work out before making the decision, said Blase Polite, MD, associate professor of medicine and the executive director for accountable care at the University of Chicago.

September 21st 2019

Dr James Hamrick Discusses Bringing Value to Patients Through Engagement

The more engaged patients who have more access to their data and are more informed about what’s going on are actually going to have better outcomes most of the time, explained James Hamrick, MD, senior medical director at Flatiron Health.

September 20th 2019

Florida Cancer Specialists & Research Institute and Humana Sign Multiyear Agreement

Florida Cancer Specialists & Research Institute and Humana Inc. have signed a new multiyear agreement that provides Humana members with in-network access to FCS’ comprehensive range of oncology services.

September 18th 2019

Too Much, Too Fast: Providers Need More Time to Operationalize Medicare's New Radiation Oncology Model

Jessica Walradt

CMS' new radiation oncology payment model is slated to begin on January 1, 2020, but the significant billing changes that the model requires will require more time.

September 18th 2019

Lessons From the Field: How Practices Are Succeeding Under OCM

Jaime Rosenberg

As rising drug costs continue to take up a larger portion of the total cost of care, practices in the Oncology Care Model find themselves in control of a shrinking portion of total costs, according to anecdotes from an academic medical center and a community-based practice during the National Comprehensive Cancer Network’s Policy Summit held September 12 in Washington, DC.

September 15th 2019

Lani Alison Discusses How the OCM Allowed for Better Integration of Palliative Care

Lani M. Alison, BSN, MS, HCQ, PCMH, CCE, vice president of Clinical Affairs, Regional Cancer Care Associates, explains how the implementation of the Oncology Care Model (OCM) allowed practices to better integrate palliative care.

September 10th 2019

Dr Iuliana Shapira Offers Examples of How Innovation Can Transform Cancer Care Delivery

Innovation that transform cancer care delivery have to be multi-level, explained Iuliana Shapira, MD, chief medical officer, Regional Cancer Care Associates.

September 7th 2019

Mike Fazio: Practices Are Happier With PP4 Results in the OCM

There are less surprises in the results for performance period 4 of the Oncology Care Model, and practices seem to be mostly happier with how they’ve done, said Mike Fazio, senior vice president of client services, Archway Health.

...

22 23 24 25 26 27 28 29 30

...

185 >

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

Do Not Sell My Information

Terms & Conditions